肿瘤细胞治疗研究
FRONTIER PAPERS
Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review.
CD19在早期阶段即表达于B细胞，并在大多数B细胞恶性肿瘤中表达，但在造血干细胞或其他正常组织中不表达，因此使其成为治疗复发或难治性（R/R）大B细胞淋巴瘤患者的一个有吸引力的治疗靶点。
Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.
Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.
M1 处的不完整响应不应自动提示观察并等待。
Racial and ethnic disparities in brain-to-vein time among patients receiving CD19 CAR-T cell therapy for relapsed/refractory DLBCL.
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-
为了解决这一问题，我们开发了一种新的复合终点：6个月无严重毒性且无进展生存期（TPFS6），定义为CAR-T治疗后6个月内无严重CRS、ICANS、进展/稳定疾病（PD/SD）和非复发死亡（NRM）。
Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice.
然而，超过 50% 的患者在接受 CAR-T 治疗后复发。
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymp
为了比较CAR-T 细胞（CART）治疗和异基因干细胞移植（alloSCT）在IPI风险因素相关的结果，我们分析了515例接受CART（n = 303）或alloSCT（n = 212）作为三线治疗的LBCL患者，这些患者注册于EBMT（2016-2021年）。
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the
在这项大型EBMT分析中，氟达拉滨剂量递增并未改善tisa-cel在LBCL中的结局，而axi-cel则与更优的疗效相关。
Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies.
嵌合抗原受体（CAR）-T细胞疗法已经改变了大B细胞淋巴瘤（LBCL）的治疗格局，尤其是在复发或难治性患者中。
Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
